Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AdaptHealth Corp (AHCO) vs Gilead Sciences, Inc. (GILD) Price & Performance

AdaptHealth CorpTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

AdaptHealth Corp vs Gilead Sciences, Inc. — how do they compare? AdaptHealth Corp trades at $5.75 (market cap $753.09M), while Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 223.5× AdaptHealth Corp's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.

AHCOGILD
Market Cap
$753.09M$168.35B
Sector
HealthHealth
52-Week High
$13.38$155.80
52-Week Low
$5.22$110.56
Enterprise Value
$2.77B$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AdaptHealth Corp

AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.

Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.

The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AdaptHealth Corp

AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.

Read more on AHCO

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD